Epigenetic Modifiers as Therapeutic Targets in Pediatric T-cell Acute Lymphoblastic Leukemia |
Washington University / Grant Challen, PhD |
'A' Award Grants |
2012 |
Missouri |
The Role of Inherited MLL3 Single Nucleotide Variants and Fetal Epigenetic Programming in Infant Leukemogenesis |
Washington University / Jeffrey Magee, MD/PhD |
'A' Award Grants |
2016 |
Missouri |
An Engineered Nanoimmunotherapy for Treating Neuroblastoma |
George Washington University / Rohan Fernandes, PhD |
'A' Award Grants |
2016 |
District of Columbia |
Rational Combination Therapy of AML |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD, PhD |
'A' Award Grants |
2013 |
New York |
Engineering the Lymph Node Environment with Therapeutic Vaccine Depots to Combat Neuroblastoma |
University of Maryland, College Park / Christopher Jewell, PhD |
'A' Award Grants |
2013 |
Maryland |
Uncovering the signaling mechanisms allowing medulloblastoma progenitor cells to orchestrate tumor relapse |
Medical University of South Carolina / Jezabel Rodriguez Blanco, PhD |
'A' Award Grants |
2023 |
South Carolina |
Investigating the Role of Genetic and Epigenetic Variation in Risk of Childhood Acute Lymphoblastic Leukemia in Down Syndrome |
University of California San Francisco / Adam de Smith, Ph.D. |
'A' Award Grants |
2014 |
California |
The Role of the Innate Immune System in Immune Dysregulation following CART |
Children’s Hospital of Philadelphia / Caroline Diorio, MD |
'A' Award Grants |
2023 |
Pennsylvania |
Mechanisms of PAX3-FOXO1 and HES3 Cooperation in Rhabdomyosarcoma |
Nationwide Children’s Hospital / Genevieve Kendall, PhD |
'A' Award Grants |
2018 |
Ohio |
Turning Killers into THINKers: TME Hostility-Impervious NK Cells for Treating Neuroblastoma and Sarcoma |
Baylor College of Medicine / Robin Parihar, MD/PhD |
'A' Award Grants |
2021 |
Texas |